IgA Nephropathy clinical trials at UCSF

1 in progress, 0 open to eligible people

Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Sorry, not currently recruiting here
The primary objective of this study to evaluate the efficacy of ravulizumab compared with placebo to reduce proteinuria and slow the rate of eGFR decline in adult participants with IgAN who are at risk of disease progression.
San Francisco, California and other locations

Last updated: May 2, 2024